Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human thrombopoietin for secondary prevention of XELOX-induced thrombocytopenia in stage III colorectal cancer
ChiCTR2000040027Phase 4Recruiting
- Sponsor
- Ordos Central Hospital
- Start
- Jun 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia (CIT) and colorectal cancer (CRC), sponsored by Ordos Central Hospital. Primary endpoint: platelet count. Started Jun 2018; status: recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2000040027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040027.